EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Implementation of a High-Dose Interleukin-2 Immunostimulation Biotherapy Program

C. Spencer Yost, Adil Daud, Michael A. Gropper

ICU Director · 2010

DOI: 10.1177/1944451610363596 ↗
AbstractBibliografische Angaben

Abstract

Interleukin-2 (IL-2) is a cytokine that produces an in vivo immunostimulating effect when given systemically. This action may arise from stimulating the growth and expansion of cytotoxic T cells that in turn activate natural killer cells to attack tumors such as malignant melanoma and renal cell carcinoma. Therefore, administration of high-dose IL-2 can invoke an antitumor response in some patients. However, high-dose IL-2 induces severe and sometimes life-threatening toxicity, including vascular leak syndrome, hypotension, fever, and end-organ damage. Renal, hepatic, pulmonary, cardiac, and neurologic side effects have been described. Patients receiving IL-2 therefore require close monitoring to detect and treat life-threatening complications arising from treatment. The authors describe the steps taken to begin an IL-2 biotherapy program in a small ICU at a regional comprehensive cancer center. The addition of “elective” IL-2 admissions to the ICU has had a beneficial effect on stabilizing the daily census. In addition, it has brought a new cohort of patients who are highly appreciative of the care they receive and provides the nursing staff a new opportunity to develop expertise with cancer biotherapy.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →